Our research is made possible by the generous support of these organisations.
Primary funder of the Jackson Synapse Targeting Lab. Alzheimer's Society is the UK's leading dementia charity, funding world-class research into the cause, prevention, diagnosis and treatment of dementia.
alzheimers.org.ukThe UK's leading dementia research charity, dedicated to defeating dementia through research. ARUK funds pioneering studies to transform understanding and treatment of diseases like Alzheimer's.
alzheimersresearchuk.orgA private medical research charity that funds innovative biomedical research across a wide range of conditions, with a focus on early-stage translational projects with high scientific promise.
rosetreestrust.co.ukA philanthropic fund supporting dementia research.
A US-based nonprofit organisation funding breakthrough research into Alzheimer's disease, macular degeneration, and glaucoma. BrightFocus supports early-career researchers advancing knowledge of these devastating conditions.
brightfocus.orgA global biotechnology company pioneering neuroscience therapies. Biogen's support enables translational research into synaptic targets of relevance to Alzheimer's disease and other neurodegenerative conditions.
biogen.comA national research initiative co-funded by the Medical Research Council, Alzheimer's Society, and Alzheimer's Research UK. UKDRI provides the infrastructure and collaborative environment for our work at Imperial College London.
ukdri.ac.ukInstitutional support and infrastructure provided by Imperial College London, one of the world's top universities for science and medicine, hosting the UK DRI Centre at Imperial.
imperial.ac.ukDementia affects over 55 million people worldwide and remains without a cure. Our research into synaptic vulnerability in Alzheimer's disease could open new therapeutic avenues. If you are interested in supporting our work — whether through philanthropic giving, industry partnerships, or collaborative grants — we would love to hear from you.